Nelson Aluya
Internal Medicine · Hillside, NJNPI 1942457916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novo Nordisk at 29.9% of the total. Reporting peaked in 2019 at $1,762 and has fallen 94.3% since, to $100 in 2025.
Across 176 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$231
- Amgen$224
- Boehringer Ingelheim$224
- Novartis$213
- Johnson & Johnson$193
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,683100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $1,101 |
| Lilly USA, LLC | 21 | $231 |
| Amgen | 16 | $224 |
| Boehringer Ingelheim | 9 | $224 |
| Novartis | 10 | $213 |
| Johnson & Johnson | 14 | $193 |
| Pfizer | 4 | $176 |
| GSK | 5 | $173 |
| Merck | 12 | $152 |
| Tactile Systems Technology Inc | 1 | $150 |
| Boston Scientific | 1 | $127 |
| Amarin Pharma, Inc. | 8 | $111 |
| AbbVie | 1 | $97 |
| Global Blood Therapeutics, Inc. | 1 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| E.r. Squibb & Sons, L.L.C. | 5 | $56 |
| AstraZeneca | 3 | $53 |
| Gilead | 3 | $45 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Edwards Lifesciences | 1 | $41 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flexitouch Plus$150
- Entre Plus$150
- GENERAL - THERAPIES$127
- JARDIANCE$125
- Ozempic$125
- OXBRYTA$125
- Tresiba$125
- RYBELSUS$124
- BEXSERO$110
How this compares
$3,683 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsentressRaltegravir Potassium | 12 | $25,578 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $22,628 |
| OzempicSemaglutide | 12 | $20,014 |
| MounjaroTirzepatide | 17 | $17,899 |
| XifaxanRifaximin | 22 | $14,037 |
| JanuviaSitagliptin Phosphate | 17 | $11,697 |
| VelphoroSucroferric Oxyhydroxide | 11 | $9,401 |
| XareltoRivaroxaban | 43 | $9,261 |
| EliquisApixaban | 22 | $8,520 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $5,764 |
| Divalproex Sodium | 72 | $4,346 |
| Atorvastatin Calcium | 155 | $2,633 |
| Mirtazapine | 55 | $2,393 |
| Levetiracetam | 66 | $2,387 |
| Sevelamer Carbonate | 13 | $2,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckIsentress, Janumet Xr, Januvia | $152 | $59,90351 claims |
| Novo NordiskOzempic | $1,101 | $20,01412 claims |
| Lilly USA, LLCMounjaro | $231 | $17,89917 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $14 | $14,03722 claims |
| Johnson & JohnsonXarelto | $193 | $9,26143 claims |
| PfizerEliquis | $176 | $8,52022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Hillside
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.